English
简体中文
Total: £ 56.28
Published Date: 2025-05-28 | Pages: 99 | Tables: 100 | Pharma & Healthcare
The global market for Dry Eye Disease Drug was valued at US$ 5876 million in the year 2024 and is projected to reach a revised size of US$ 7976 million by 2031, growing at a CAGR of 4.5% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Dry Eye Disease Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Dry Eye Disease (DED) drugs are pharmaceutical treatments designed to alleviate the symptoms and underlying causes of dry eye disease, a chronic condition characterized by insufficient tear production or poor tear quality. These drugs aim to restore tear film stability, reduce inflammation, and improve ocular surface health. Common types of DED drugs include artificial tears, anti-inflammatory agents like cyclosporine and lifitegrast, and medications that stimulate tear production. These treatments help relieve discomfort, prevent further eye damage, and enhance patients’ quality of life.
The Dry Eye Disease (DED) Drug market is driven by the increasing prevalence of dry eye disease worldwide, largely due to aging populations, widespread digital device use, and environmental factors such as pollution and dry climates. Rising awareness about ocular health and improved diagnostic capabilities have led to higher rates of diagnosis and treatment initiation. Moreover, advancements in pharmaceutical research have introduced innovative drugs like lifitegrast and novel formulations of cyclosporine, offering better efficacy and patient compliance compared to traditional artificial tears. Growing demand from both developed and emerging markets, coupled with supportive government initiatives and reimbursement policies, continues to fuel the expansion of the DED drug market.
Despite promising growth, the Dry Eye Disease Drug market faces several challenges. The complex and multifactorial nature of dry eye disease makes it difficult to develop universally effective treatments, as patients often require personalized therapy regimens. Many existing drugs provide symptomatic relief rather than a permanent cure, which can lead to patient dissatisfaction and poor adherence. Additionally, high treatment costs and limited access to advanced therapies in low-income regions restrict market penetration. Regulatory hurdles and long approval timelines for novel drugs further slow market entry. To overcome these challenges, ongoing research into better-targeted therapies and cost-effective treatment options is essential.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Dry Eye Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dry Eye Disease Drug.
The Dry Eye Disease Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dry Eye Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dry Eye Disease Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AbbVie
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group
OmniVision Pharma
Rohto
Prestige Consumer Healthcare
LION
Kenvue (VISINE)
Segment by Type
Artificial Tears
Anti-inflammatory Drugs
Other
Segment by Application
Hospital
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dry Eye Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dry Eye Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Dry Eye Disease Drug Market Overview
1.1 Product Definition
1.2 Dry Eye Disease Drug by Type
1.2.1 Global Dry Eye Disease Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Artificial Tears
1.2.3 Anti-inflammatory Drugs
1.2.4 Other
1.3 Dry Eye Disease Drug by Application
1.3.1 Global Dry Eye Disease Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Dry Eye Disease Drug Market Size Estimates and Forecasts
1.4.1 Global Dry Eye Disease Drug Revenue 2020-2031
1.4.2 Global Dry Eye Disease Drug Sales 2020-2031
1.4.3 Global Dry Eye Disease Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Dry Eye Disease Drug Market Competition by Manufacturers
2.1 Global Dry Eye Disease Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Dry Eye Disease Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Dry Eye Disease Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Dry Eye Disease Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Dry Eye Disease Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dry Eye Disease Drug, Product Type & Application
2.7 Global Key Manufacturers of Dry Eye Disease Drug, Date of Enter into This Industry
2.8 Global Dry Eye Disease Drug Market Competitive Situation and Trends
2.8.1 Global Dry Eye Disease Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Dry Eye Disease Drug Players Market Share by Revenue
2.8.3 Global Dry Eye Disease Drug Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Dry Eye Disease Drug Market Scenario by Region
3.1 Global Dry Eye Disease Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Dry Eye Disease Drug Sales by Region: 2020-2031
3.2.1 Global Dry Eye Disease Drug Sales by Region: 2020-2025
3.2.2 Global Dry Eye Disease Drug Sales by Region: 2026-2031
3.3 Global Dry Eye Disease Drug Revenue by Region: 2020-2031
3.3.1 Global Dry Eye Disease Drug Revenue by Region: 2020-2025
3.3.2 Global Dry Eye Disease Drug Revenue by Region: 2026-2031
3.4 North America Dry Eye Disease Drug Market Facts & Figures by Country
3.4.1 North America Dry Eye Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Dry Eye Disease Drug Sales by Country (2020-2031)
3.4.3 North America Dry Eye Disease Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Dry Eye Disease Drug Market Facts & Figures by Country
3.5.1 Europe Dry Eye Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Dry Eye Disease Drug Sales by Country (2020-2031)
3.5.3 Europe Dry Eye Disease Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dry Eye Disease Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Dry Eye Disease Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Dry Eye Disease Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Dry Eye Disease Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Dry Eye Disease Drug Market Facts & Figures by Country
3.7.1 Latin America Dry Eye Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Dry Eye Disease Drug Sales by Country (2020-2031)
3.7.3 Latin America Dry Eye Disease Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dry Eye Disease Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Dry Eye Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Dry Eye Disease Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Dry Eye Disease Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Dry Eye Disease Drug Sales by Type (2020-2031)
4.1.1 Global Dry Eye Disease Drug Sales by Type (2020-2025)
4.1.2 Global Dry Eye Disease Drug Sales by Type (2026-2031)
4.1.3 Global Dry Eye Disease Drug Sales Market Share by Type (2020-2031)
4.2 Global Dry Eye Disease Drug Revenue by Type (2020-2031)
4.2.1 Global Dry Eye Disease Drug Revenue by Type (2020-2025)
4.2.2 Global Dry Eye Disease Drug Revenue by Type (2026-2031)
4.2.3 Global Dry Eye Disease Drug Revenue Market Share by Type (2020-2031)
4.3 Global Dry Eye Disease Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Dry Eye Disease Drug Sales by Application (2020-2031)
5.1.1 Global Dry Eye Disease Drug Sales by Application (2020-2025)
5.1.2 Global Dry Eye Disease Drug Sales by Application (2026-2031)
5.1.3 Global Dry Eye Disease Drug Sales Market Share by Application (2020-2031)
5.2 Global Dry Eye Disease Drug Revenue by Application (2020-2031)
5.2.1 Global Dry Eye Disease Drug Revenue by Application (2020-2025)
5.2.2 Global Dry Eye Disease Drug Revenue by Application (2026-2031)
5.2.3 Global Dry Eye Disease Drug Revenue Market Share by Application (2020-2031)
5.3 Global Dry Eye Disease Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Company Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AbbVie Dry Eye Disease Drug Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Alcon
6.2.1 Alcon Company Information
6.2.2 Alcon Description and Business Overview
6.2.3 Alcon Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Alcon Dry Eye Disease Drug Product Portfolio
6.2.5 Alcon Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis Dry Eye Disease Drug Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Santen Pharma
6.4.1 Santen Pharma Company Information
6.4.2 Santen Pharma Description and Business Overview
6.4.3 Santen Pharma Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Santen Pharma Dry Eye Disease Drug Product Portfolio
6.4.5 Santen Pharma Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Johnson & Johnson Dry Eye Disease Drug Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Bausch & Lomb
6.6.1 Bausch & Lomb Company Information
6.6.2 Bausch & Lomb Description and Business Overview
6.6.3 Bausch & Lomb Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bausch & Lomb Dry Eye Disease Drug Product Portfolio
6.6.5 Bausch & Lomb Recent Developments/Updates
6.7 Thea pharmaceuticals
6.7.1 Thea pharmaceuticals Company Information
6.7.2 Thea pharmaceuticals Description and Business Overview
6.7.3 Thea pharmaceuticals Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Thea pharmaceuticals Dry Eye Disease Drug Product Portfolio
6.7.5 Thea pharmaceuticals Recent Developments/Updates
6.8 URSAPHARM
6.8.1 URSAPHARM Company Information
6.8.2 URSAPHARM Description and Business Overview
6.8.3 URSAPHARM Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 URSAPHARM Dry Eye Disease Drug Product Portfolio
6.8.5 URSAPHARM Recent Developments/Updates
6.9 SIMILASAN
6.9.1 SIMILASAN Company Information
6.9.2 SIMILASAN Description and Business Overview
6.9.3 SIMILASAN Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 SIMILASAN Dry Eye Disease Drug Product Portfolio
6.9.5 SIMILASAN Recent Developments/Updates
6.10 Akorn
6.10.1 Akorn Company Information
6.10.2 Akorn Description and Business Overview
6.10.3 Akorn Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Akorn Dry Eye Disease Drug Product Portfolio
6.10.5 Akorn Recent Developments/Updates
6.11 United Laboratories
6.11.1 United Laboratories Company Information
6.11.2 United Laboratories Description and Business Overview
6.11.3 United Laboratories Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 United Laboratories Dry Eye Disease Drug Product Portfolio
6.11.5 United Laboratories Recent Developments/Updates
6.12 Sun Pharmaceutical
6.12.1 Sun Pharmaceutical Company Information
6.12.2 Sun Pharmaceutical Description and Business Overview
6.12.3 Sun Pharmaceutical Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Sun Pharmaceutical Dry Eye Disease Drug Product Portfolio
6.12.5 Sun Pharmaceutical Recent Developments/Updates
6.13 Jianfeng Group
6.13.1 Jianfeng Group Company Information
6.13.2 Jianfeng Group Description and Business Overview
6.13.3 Jianfeng Group Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Jianfeng Group Dry Eye Disease Drug Product Portfolio
6.13.5 Jianfeng Group Recent Developments/Updates
6.14 OmniVision Pharma
6.14.1 OmniVision Pharma Company Information
6.14.2 OmniVision Pharma Description and Business Overview
6.14.3 OmniVision Pharma Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.14.4 OmniVision Pharma Dry Eye Disease Drug Product Portfolio
6.14.5 OmniVision Pharma Recent Developments/Updates
6.15 Rohto
6.15.1 Rohto Company Information
6.15.2 Rohto Description and Business Overview
6.15.3 Rohto Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Rohto Dry Eye Disease Drug Product Portfolio
6.15.5 Rohto Recent Developments/Updates
6.16 Prestige Consumer Healthcare
6.16.1 Prestige Consumer Healthcare Company Information
6.16.2 Prestige Consumer Healthcare Description and Business Overview
6.16.3 Prestige Consumer Healthcare Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Prestige Consumer Healthcare Dry Eye Disease Drug Product Portfolio
6.16.5 Prestige Consumer Healthcare Recent Developments/Updates
6.17 LION
6.17.1 LION Company Information
6.17.2 LION Description and Business Overview
6.17.3 LION Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.17.4 LION Dry Eye Disease Drug Product Portfolio
6.17.5 LION Recent Developments/Updates
6.18 Kenvue (VISINE)
6.18.1 Kenvue (VISINE) Company Information
6.18.2 Kenvue (VISINE) Description and Business Overview
6.18.3 Kenvue (VISINE) Dry Eye Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Kenvue (VISINE) Dry Eye Disease Drug Product Portfolio
6.18.5 Kenvue (VISINE) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dry Eye Disease Drug Industry Chain Analysis
7.2 Dry Eye Disease Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dry Eye Disease Drug Production Mode & Process Analysis
7.4 Dry Eye Disease Drug Sales and Marketing
7.4.1 Dry Eye Disease Drug Sales Channels
7.4.2 Dry Eye Disease Drug Distributors
7.5 Dry Eye Disease Drug Customer Analysis
8 Dry Eye Disease Drug Market Dynamics
8.1 Dry Eye Disease Drug Industry Trends
8.2 Dry Eye Disease Drug Market Drivers
8.3 Dry Eye Disease Drug Market Challenges
8.4 Dry Eye Disease Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Dry Eye Disease Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Dry Eye Disease Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Dry Eye Disease Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Dry Eye Disease Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Dry Eye Disease Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Dry Eye Disease Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Dry Eye Disease Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Dry Eye Disease Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Dry Eye Disease Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Dry Eye Disease Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Dry Eye Disease Drug, Product Type & Application
Table 12. Global Key Manufacturers of Dry Eye Disease Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Dry Eye Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dry Eye Disease Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Dry Eye Disease Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Dry Eye Disease Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Dry Eye Disease Drug Sales Market Share by Region (2020-2025)
Table 19. Global Dry Eye Disease Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Dry Eye Disease Drug Sales Market Share by Region (2026-2031)
Table 21. Global Dry Eye Disease Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Dry Eye Disease Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Dry Eye Disease Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Dry Eye Disease Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Dry Eye Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Dry Eye Disease Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Dry Eye Disease Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Dry Eye Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Dry Eye Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Dry Eye Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Dry Eye Disease Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Dry Eye Disease Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Dry Eye Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Dry Eye Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Dry Eye Disease Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Dry Eye Disease Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Dry Eye Disease Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Dry Eye Disease Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Dry Eye Disease Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Dry Eye Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Dry Eye Disease Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Dry Eye Disease Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Dry Eye Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Dry Eye Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Dry Eye Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Dry Eye Disease Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Dry Eye Disease Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Dry Eye Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Dry Eye Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Dry Eye Disease Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Dry Eye Disease Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Dry Eye Disease Drug Sales Market Share by Type (2020-2025)
Table 53. Global Dry Eye Disease Drug Sales Market Share by Type (2026-2031)
Table 54. Global Dry Eye Disease Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Dry Eye Disease Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Dry Eye Disease Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Dry Eye Disease Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Dry Eye Disease Drug Price (US$/Unit) by Type (2020-2025)
Table 59. Global Dry Eye Disease Drug Price (US$/Unit) by Type (2026-2031)
Table 60. Global Dry Eye Disease Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Dry Eye Disease Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Dry Eye Disease Drug Sales Market Share by Application (2020-2025)
Table 63. Global Dry Eye Disease Drug Sales Market Share by Application (2026-2031)
Table 64. Global Dry Eye Disease Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Dry Eye Disease Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Dry Eye Disease Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Dry Eye Disease Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Dry Eye Disease Drug Price (US$/Unit) by Application (2020-2025)
Table 69. Global Dry Eye Disease Drug Price (US$/Unit) by Application (2026-2031)
Table 70. AbbVie Company Information
Table 71. AbbVie Description and Business Overview
Table 72. AbbVie Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. AbbVie Dry Eye Disease Drug Product
Table 74. AbbVie Recent Developments/Updates
Table 75. Alcon Company Information
Table 76. Alcon Description and Business Overview
Table 77. Alcon Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Alcon Dry Eye Disease Drug Product
Table 79. Alcon Recent Developments/Updates
Table 80. Novartis Company Information
Table 81. Novartis Description and Business Overview
Table 82. Novartis Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Novartis Dry Eye Disease Drug Product
Table 84. Novartis Recent Developments/Updates
Table 85. Santen Pharma Company Information
Table 86. Santen Pharma Description and Business Overview
Table 87. Santen Pharma Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Santen Pharma Dry Eye Disease Drug Product
Table 89. Santen Pharma Recent Developments/Updates
Table 90. Johnson & Johnson Company Information
Table 91. Johnson & Johnson Description and Business Overview
Table 92. Johnson & Johnson Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Johnson & Johnson Dry Eye Disease Drug Product
Table 94. Johnson & Johnson Recent Developments/Updates
Table 95. Bausch & Lomb Company Information
Table 96. Bausch & Lomb Description and Business Overview
Table 97. Bausch & Lomb Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Bausch & Lomb Dry Eye Disease Drug Product
Table 99. Bausch & Lomb Recent Developments/Updates
Table 100. Thea pharmaceuticals Company Information
Table 101. Thea pharmaceuticals Description and Business Overview
Table 102. Thea pharmaceuticals Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Thea pharmaceuticals Dry Eye Disease Drug Product
Table 104. Thea pharmaceuticals Recent Developments/Updates
Table 105. URSAPHARM Company Information
Table 106. URSAPHARM Description and Business Overview
Table 107. URSAPHARM Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. URSAPHARM Dry Eye Disease Drug Product
Table 109. URSAPHARM Recent Developments/Updates
Table 110. SIMILASAN Company Information
Table 111. SIMILASAN Description and Business Overview
Table 112. SIMILASAN Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. SIMILASAN Dry Eye Disease Drug Product
Table 114. SIMILASAN Recent Developments/Updates
Table 115. Akorn Company Information
Table 116. Akorn Description and Business Overview
Table 117. Akorn Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Akorn Dry Eye Disease Drug Product
Table 119. Akorn Recent Developments/Updates
Table 120. United Laboratories Company Information
Table 121. United Laboratories Description and Business Overview
Table 122. United Laboratories Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. United Laboratories Dry Eye Disease Drug Product
Table 124. United Laboratories Recent Developments/Updates
Table 125. Sun Pharmaceutical Company Information
Table 126. Sun Pharmaceutical Description and Business Overview
Table 127. Sun Pharmaceutical Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Sun Pharmaceutical Dry Eye Disease Drug Product
Table 129. Sun Pharmaceutical Recent Developments/Updates
Table 130. Jianfeng Group Company Information
Table 131. Jianfeng Group Description and Business Overview
Table 132. Jianfeng Group Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Jianfeng Group Dry Eye Disease Drug Product
Table 134. Jianfeng Group Recent Developments/Updates
Table 135. OmniVision Pharma Company Information
Table 136. OmniVision Pharma Description and Business Overview
Table 137. OmniVision Pharma Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. OmniVision Pharma Dry Eye Disease Drug Product
Table 139. OmniVision Pharma Recent Developments/Updates
Table 140. Rohto Company Information
Table 141. Rohto Description and Business Overview
Table 142. Rohto Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Rohto Dry Eye Disease Drug Product
Table 144. Rohto Recent Developments/Updates
Table 145. Prestige Consumer Healthcare Company Information
Table 146. Prestige Consumer Healthcare Description and Business Overview
Table 147. Prestige Consumer Healthcare Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Prestige Consumer Healthcare Dry Eye Disease Drug Product
Table 149. Prestige Consumer Healthcare Recent Developments/Updates
Table 150. LION Company Information
Table 151. LION Description and Business Overview
Table 152. LION Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. LION Dry Eye Disease Drug Product
Table 154. LION Recent Developments/Updates
Table 155. Kenvue (VISINE) Company Information
Table 156. Kenvue (VISINE) Description and Business Overview
Table 157. Kenvue (VISINE) Dry Eye Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. Kenvue (VISINE) Dry Eye Disease Drug Product
Table 159. Kenvue (VISINE) Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Dry Eye Disease Drug Distributors List
Table 163. Dry Eye Disease Drug Customers List
Table 164. Dry Eye Disease Drug Market Trends
Table 165. Dry Eye Disease Drug Market Drivers
Table 166. Dry Eye Disease Drug Market Challenges
Table 167. Dry Eye Disease Drug Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
Table 171. Authors List of This Report
List of Figures
Figure 1. Product Picture of Dry Eye Disease Drug
Figure 2. Global Dry Eye Disease Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Dry Eye Disease Drug Market Share by Type: 2024 & 2031
Figure 4. Artificial Tears Product Picture
Figure 5. Anti-inflammatory Drugs Product Picture
Figure 6. Other Product Picture
Figure 7. Global Dry Eye Disease Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Dry Eye Disease Drug Market Share by Application: 2024 & 2031
Figure 9. Hospital
Figure 10. Retail Pharmacy
Figure 11. Others
Figure 12. Global Dry Eye Disease Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Dry Eye Disease Drug Market Size (2020-2031) & (US$ Million)
Figure 14. Global Dry Eye Disease Drug Sales (2020-2031) & (K Units)
Figure 15. Global Dry Eye Disease Drug Average Price (US$/Unit) & (2020-2031)
Figure 16. Dry Eye Disease Drug Report Years Considered
Figure 17. Dry Eye Disease Drug Sales Share by Manufacturers in 2024
Figure 18. Global Dry Eye Disease Drug Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Dry Eye Disease Drug Players: Market Share by Revenue in Dry Eye Disease Drug in 2024
Figure 20. Dry Eye Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Dry Eye Disease Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Dry Eye Disease Drug Sales Market Share by Country (2020-2031)
Figure 23. North America Dry Eye Disease Drug Revenue Market Share by Country (2020-2031)
Figure 24. United States Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Dry Eye Disease Drug Sales Market Share by Country (2020-2031)
Figure 27. Europe Dry Eye Disease Drug Revenue Market Share by Country (2020-2031)
Figure 28. Germany Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Dry Eye Disease Drug Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Dry Eye Disease Drug Revenue Market Share by Region (2020-2031)
Figure 35. China Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Indonesia Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Thailand Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Malaysia Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Dry Eye Disease Drug Sales Market Share by Country (2020-2031)
Figure 45. Latin America Dry Eye Disease Drug Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Dry Eye Disease Drug Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Dry Eye Disease Drug Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Dry Eye Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Dry Eye Disease Drug by Type (2020-2031)
Figure 55. Global Revenue Market Share of Dry Eye Disease Drug by Type (2020-2031)
Figure 56. Global Dry Eye Disease Drug Price (US$/Unit) by Type (2020-2031)
Figure 57. Global Sales Market Share of Dry Eye Disease Drug by Application (2020-2031)
Figure 58. Global Revenue Market Share of Dry Eye Disease Drug by Application (2020-2031)
Figure 59. Global Dry Eye Disease Drug Price (US$/Unit) by Application (2020-2031)
Figure 60. Dry Eye Disease Drug Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
